CTXR Citius Pharmaceuticals, Inc.
Healthcare$0.70-0.58%ClosedMarket Cap: $7.8M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
0.25
P/S
1.40
EV/EBITDA
-0.07
DCF Value
$0.92
FCF Yield
-403.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
37.4%
Operating Margin
-1041.4%
Net Margin
-823.3%
ROE
-67.4%
ROA
-34.9%
ROIC
-75.2%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q2 null | $1.7M | -22.9% | $-32.2M | $-21.2M | $— | — |
| Q1 null | $3.9M | 65.5% | $-9.0M | $-8.2M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-8.4M | $-8.0M | $— | — |
| FY null | $0.00 | -Infinity% | $-38.5M | $-37.4M | $— | — |
| Q3 null | $0.00 | -Infinity% | $-8.8M | $-8.8M | $— | — |
| Q2 null | $0.00 | NaN% | $-11.3M | $-10.9M | $— | — |
| Q1 null | $0.00 | NaN% | $-10.0M | $-9.8M | $— | — |
| Q4 null | $155.9K | -34.4% | $-11.1M | $-10.8M | $— | — |
| FY null | $0.00 | -Infinity% | $-42.0M | $-39.1M | $— | — |
| Q3 null | $0.00 | -Infinity% | $-10.6M | $-10.6M | $— | — |
| Q2 null | $0.00 | -Infinity% | $-11.0M | $-8.5M | $— | — |
| Q1 2024 | $0.00 | -Infinity% | $-9.3M | $-9.2M | $-1.45 | — |